DexCom, Inc. (DXCM)
Largest Insider Buys in Sector
DXCM Stock Price History Chart
DXCM Stock Performance
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is …
Insider Activity of DexCom, Inc.
Over the last 12 months, insiders at DexCom, Inc. have bought $0 and sold $38.66M worth of DexCom, Inc. stock.
On average, over the past 5 years, insiders at DexCom, Inc. have bought $0 and sold $74.42M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $2.5M was made by ALTMAN STEVEN R (director) on 2017‑11‑07.
List of Insider Buy and Sell Transactions, DexCom, Inc.
| 2024-11-15 | Sale | EVP, Chief Financal Officer | 3,500 0.0009% | $75.51 | $264,285 | -0.84% | ||
| 2024-09-16 | Sale | director | 1,000 0.0002% | $70.00 | $70,000 | -0.67% | ||
| 2024-09-09 | Sale | EVP, Chief Operating Officer | 746 0.0002% | $69.15 | $51,586 | -0.22% | ||
| 2024-09-09 | Sale | EVP, Chief Financal Officer | 746 0.0002% | $69.15 | $51,586 | -0.22% | ||
| 2024-09-09 | Sale | EVP, Chief HR Officer | 426 0.0001% | $69.15 | $29,458 | -0.22% | ||
| 2024-08-30 | Sale | EVP, Chief Legal Officer | 686 0.0002% | $70.00 | $48,020 | +0.36% | ||
| 2024-07-31 | Sale | EVP, Chief Legal Officer | 652 0.0002% | $69.55 | $45,347 | 0.00% | ||
| 2024-06-28 | Sale | EVP Chief Legal Officer | 659 0.0002% | $114.29 | $75,317 | 0.00% | ||
| 2024-06-18 | Sale | director | 3,306 0.0008% | $116.79 | $386,122 | -39.71% | ||
| 2024-06-17 | Sale | director | 2,694 0.0007% | $117.26 | $315,907 | -39.64% | ||
| 2024-06-14 | Sale | director | 1,000 0.0002% | $113.55 | $113,550 | -39.33% | ||
| 2024-06-10 | Sale | EVP Chief Operating Officer | 745 0.0002% | $115.05 | $85,713 | -39.54% | ||
| 2024-06-10 | Sale | EVP Chief Financial Officer | 745 0.0002% | $115.05 | $85,713 | -39.54% | ||
| 2024-06-10 | Sale | EVP Chief HR Officer | 427 0.0001% | $115.05 | $49,127 | -39.54% | ||
| 2024-05-31 | Sale | EVP Chief Legal Officer | 652 0.0002% | $119.24 | $77,744 | -39.80% | ||
| 2024-05-15 | Sale | EVP Strategy and Corporate Dev | 2,423 0.0006% | $126.58 | $306,703 | -44.27% | ||
| 2024-04-30 | Sale | EVP Chief Legal Officer | 629 0.0002% | $126.25 | $79,411 | -43.00% | ||
| 2024-04-15 | Sale | EVP Strategy and Corporate Dev | 1,990 0.0005% | $137.81 | $274,242 | -44.42% | ||
| 2024-04-08 | Sale | President CEO and Chairman | 49,633 0.0127% | $138.30 | $6.86M | -45.78% | ||
| 2024-03-28 | Sale | EVP Chief Legal Officer | 2,624 0.0007% | $140.04 | $367,472 | -20.47% |
Insider Historical Profitability
| Pacelli Steven Robert | EVP Managing Director Dexcom V | 124775 0.0319% | $74.69 | 1 | 133 | +177.84% |
| ALTMAN STEVEN R | director | 53132 0.0136% | $74.69 | 2 | 19 | +71.25% |
| NELSON GLEN D | director | 170654 0.0437% | $74.69 | 1 | 0 | +17.09% |
| LUCAS DONALD L | director | 69076 0.0177% | $74.69 | 1 | 2 | +17.09% |
| LORD JONATHAN T MD | director | 52820 0.0135% | $74.69 | 2 | 8 | +22.29% |
Institutional Investor Ownership
| The Vanguard Group | $6.19B | 11.22 | 44.6M | +0.31% | +$18.9M | 0.11 | |
| BlackRock | $4.71B | 8.53 | 33.92M | +3.66% | +$165.95M | 0.1 | |
| State Street | $2.25B | 4.08 | 16.21M | +0.1% | +$2.25M | 0.09 | |
| Baillie Gifford Co | $2.18B | 3.95 | 15.69M | -5.04% | -$115.39M | 1.69 | |
| Capital Research Global Investors | $1.86B | 3.38 | 13.44M | -12.16% | -$258M | 0.42 |